Drug intelligence / Profile preview

Mesolipo

Development stage: Unknown
Lead developer: Instituto Antony Barbosa
Modality: Small Molecules
Administration: Subcutaneous, Intradermal

Overview

Mesolipo is a proprietary mesotherapy protocol developed by the Antony Barbosa Institute (Antony de Paula Barbosa) for the treatment of localized adiposity. The protocol involves the administration of a lipolytic cocktail via intradermal or subcutaneous injections into targeted areas of fat accumulation, such as the abdomen or flanks. It is designed to promote the breakdown of adipose tissue and improve body contouring through a combination of active substances that stimulate lipolysis and improve local microcirculation. The Mesolipo protocol has been evaluated in randomized, split-body clinical trials to determine its efficacy, safety, and patient satisfaction compared to active agents like pentoxifylline.

Brand names: Mesolipo
Other names: Mesolipo protocol

Beyond the preview

Go deeper on Mesolipo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesolipo.

Explore the full profile